Drugs / AMX-883
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07723703 | Oct 2026 → Dec 2028 expected | acute myeloid leukemia, myelodysplastic syndrome | Amphista Therapeutics Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMX-883 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07723703 ↗ |
| Route | Oral | “AMX-883 will be administered orally.” NCT07723703 ↗ |